Brought to you by 
Eisai partners with Quintiles in oncology
13 Oct 2016
Executive Summary
Furthering its newly announced product creation strategy within oncology, Eisai Co. Ltd. has partnered with CRO Quintiles to develop its cancer compounds.
Deal Industry
- Contract Research, Toxicology Testing-CRO
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Eisai partners with Quintiles in oncology
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice